Arkadios Wealth Advisors Invests $301,000 in IQVIA Holdings Inc. $IQV

Arkadios Wealth Advisors purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,909 shares of the medical research company’s stock, valued at approximately $301,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IQV. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the period. AllSquare Wealth Management LLC acquired a new position in shares of IQVIA in the 1st quarter valued at about $33,000. Trust Co. of Toledo NA OH acquired a new position in shares of IQVIA in the 2nd quarter valued at about $39,000. J.Safra Asset Management Corp lifted its holdings in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares during the period. Finally, Larson Financial Group LLC lifted its holdings in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after buying an additional 144 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQV stock opened at $210.19 on Thursday. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $225.91. The business has a fifty day moving average of $198.53 and a two-hundred day moving average of $175.34. The stock has a market cap of $35.80 billion, a price-to-earnings ratio of 28.83, a price-to-earnings-growth ratio of 2.36 and a beta of 1.34. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. During the same period last year, the business posted $2.84 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. Citigroup boosted their price objective on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. Cowen cut IQVIA from a “buy” rating to a “hold” rating in a report on Monday. UBS Group upped their price target on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Finally, Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and upped their price target for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $239.94.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.